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Background: The mechanisms underlying the association between smoking and mucus overproduction remain
unknown. Because of its involvement in other airway diseases, such as asthma, we hypothesized that
Ca2+-activated Cl- channel 1 (CLCA1) was associated with overproduction of mucus in the airways of smokers and
COPD patients.
Methods: Using real-time quantitative PCR analyses, we compared the CLCA1 mRNA expression levels in
induced-sputum cells from COPD patients (n = 20), smokers without COPD (n = 5), and non-smokers (n =13). We
also examined the relationship between CLCA1 protein expression and mucus production in lung airway epithelia
of COPD patients (n = 6), smokers without COPD (n = 7), and non-smokers (n = 7).
Results: CLCA1 mRNA expression was significantly up-regulated in the induced-sputum cells of COPD patients
compared with cells of non-smokers (p = 0.02), but there was no significant difference compared with cells of
smokers without COPD. Using immunostaining with an anti-CLCA1 antibody, semi-quantitative image analyses of
airway epithelium demonstrated significantly increased CLCA1 expression in smokers without COPD (p = 0.02) and
in COPD patients (p = 0.002) compared with non-smokers. There were significant negative correlations between
CLCA1 protein expression and FEV1/FVC (r =−0.57, p = 0.01) and %predicted FEV1 (r =−0.56, p = 0.01). PAS staining
for mucus showed that there was a significant positive correlation between CLCA1 protein expression and mucus
production (r = 0.67, p = 0.001). These markers were significantly increased in smokers without COPD (p = 0.04) and
in COPD patients (p = 0.003) compared with non-smokers (non-smokers< smokers≤COPD).
Conclusions: CLCA1 expression is significantly related to mucus production in the airway epithelia of smokers and
COPD patients, and may contribute to the development and pathogenesis of COPD by inducing mucus production.
Keywords: Ca2+-activated Cl- channel 1 (CLCA1), Chronic obstructive pulmonary disease (COPD), Smoking, Mucus
production, Airway epitheliaBackground
COPD is a chronic inflammation of the airways, includ-
ing the parenchyma and the pulmonary vasculature [1].
The pathological hallmarks of COPD are destruction of
the lung parenchyma, which characterizes pulmonary
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reproduction in any medium, provided the ormucus hypersecretion. Goblet cell hyperplasia and
mucus hypersecretion are prominent features of COPD,
particularly during disease exacerbations. Mucus hyper-
secretion is associated with patient morbidity and with
mortality among certain groups of patients.
Cigarette smoking is a major risk factor for COPD de-
velopment; nearly 90% of COPD patients are smokers [2].
Cigarette smoke is a complex mixture of chemical com-
pounds, including free radicals and other oxidants, which
can potentially induce tissue damage, airway inflamma-
tion, goblet cell hyperplasia, and mucus overproductionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Subjects’ characteristics for CLCA1 mRNA expression in induced sputum
Non-smokers Smokers without COPD COPD
Number of subjects (M / F) 13 (9 / 4) 5 (5 / 0) 20 (20 / 0)
Age (yrs) 29.8 ± 2.2 33.0 ± 4.9 72.3 ± 1.1 **††
Current / ex-smokers - 5 / 0 4 / 16
Brinkman index (packyears) - 10.0 ± 2.4 52.1 ± 3.6
VC (%predicted) 99.0 ± 3.7 98.1 ± 2.2 97.8 ± 4.1
FEV1 (L) 3.5 ± 0.2 4.0 ± 0.3 1.4 ± 0.1 **††
FEV1 / FVC (%) 86.6 ± 1.5 88.4 ± 3.6 47.9 ± 2.0 **††
FEV1 (%predicted) 96.1 ± 3.3 101.7 ± 6.0 63.9 ± 5.7 **††
Results are means ± SEMs. Comparisons between groups were made by Student's t-tests (** p≤ 0.01, compared with non-smokers; †† p≤ 0.01, compared with
smokers without COPD.).




Total cells (×105cells/g) 36.6 ± 9.1 45.8 ± 17.5 39.4 ± 12.5
Macrophage (%) 35.5 ± 7.2 22.5 ± 11.2 8.3 ± 2.8 **
Lymphocyte (%) 2.9 ± 0.5 3.3 ± 0.9 3.8 ± 0.7
Neutrophil (%) 61.1 ± 7.3 73.8 ± 11.8 82.5 ± 4.0 **
Eosinophil (%) 0.5 ± 0.3 0.5 ± 0.5 5.5 ± 2.0 *
Results are means ± SEMs. Comparisons between groups were made by
Student's t-tests (* p≤ 0.05, ** p≤ 0.01, compared with non-smokers).
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ation between smoking and mucus overproduction re-
main unknown.
Chloride channels are intimately associated with mucus
secretion in the airways [5]. One of these channels, cystic
fibrosis transmembrane conductance regulator (CFTR), is
a well-known example in which defective mutations cause
cystic fibrosis (CF) characterized by abnormal airway
mucus [6-8]. CLCA is a newly identified family of chloride
channel proteins that mediate Ca2+-activated Cl- conduct-
ance. These channel proteins have 4 or 5 transmembrane
regions and are 902 to 943 amino acids in length [9].
One of the more interesting features of this family is its
wide distribution in human secretory organs [10]. The
human CLCA1 gene is expressed in the digestive tract,
including the colon, small intestine, stomach, and appen-
dix. CLCA2 is mainly expressed in the trachea, while
CLCA4 is mainly expressed in the colon and trachea. We
previously found that mCLCA3 (mouse counterpart of
CLCA1) was selectively expressed in airway goblet cells in
a murine allergic asthma model and played a critical role
in bronchial hyper-reactivity and mucus overproduction
[11]. Further, only CLCA1 (originally designated CaCC1)
was significantly up-regulated in the airway epithelium of
bronchial asthma and played a direct role in mucus pro-
duction in a human airway epithelial cell line [12].
In this study, to examine a role for CLCA1 in COPD
and a mechanistic link between smoking and mucus over-
production, we compared the CLCA1 mRNA expression
levels in induced-sputum cells from COPD patients, smo-
kers without COPD, and non-smokers using real-time
quantitative PCR analyses. We also examined the rela-
tionship between CLCA1 protein expression and mucus
production in lung airway epithelia of COPD patients,
smokers, and non-smokers.
Methods
Subjects and Sputum Collection and Analysis
The ethics committee of the Shinshu University School of
Medicine approved this study (approval No. 255), and allsubjects gave their informed consents. COPD was defined
as a forced expiratory volume in 1 second (FEV1) to
forced vital capacity (FVC) (FEV1/FVC) ratio of< 70%.
Induced-sputum cells were obtained from 20 male
patients with COPD (FEV1/FVC: 32.6-61.3%; %predicted
FEV1: 32.0-123.6% after inhaling a beta-2 bronchodilator),
5 male smokers without COPD (FEV1/FVC: 81.0-97.5%),
and 13 healthy non-smokers (FEV1/FVC: 80.8-96.1%)
(Table 1). Patients with smoking-related COPD and with-
out α1-antitrypsin deficiency were recruited from out-
patient clinics. All COPD patients had a smoking history
of≥ 30 pack-years and no history of asthma or changes in
symptoms. Based on the classifications for COPD severity
outlined in the Global initiative for chronic Obstructive
Lung Disease (GOLD) [1], 6 patients had mild COPD, 12
had moderate COPD, and 2 had severe COPD. All had
been treated with bronchodilators including regular in-
halation of an anti-cholinergic agent and/or beta-2 ago-
nists and/or slow-releasing theophylline for more than
6 months prior to this study. The 5 smokers without
COPD and the 13 normal healthy non-smokers were
non-atopic and showed no abnormalities on pulmonary
function test results.
Sputum was induced by inhalation of hypertonic saline
as previously described [13]. Total cell counts, excluding
squamous cells, were determined using a standard
hemocytometer, normalized for mass, and expressed as
cells x105/g wet-weight sputum (Table 2). Cell smears
Table 3 Subjects’ characteristics for histochemical analysis
Non-smokers Smokers without COPD COPD
Number of subjects (M / F) 7 (2 / 5) 7 (6 / 1) 6 (6 / 0)
Age (yrs) 57.0 ± 2.5 65.1 ± 3.7 65.7 ± 4.1
Current / ex-smokers - 4 / 3 0 / 6
Brinkman index (packyears) - 53.0 ± 6.9 69.2 ± 12.3
VC (%predicted) 107.9 ± 3.8 95.6 ± 3.9 * 94.3 ± 2.1 *
FEV1 (L) 2.4 ± 0.1 2.4 ± 0.3 2.1 ± 0.1
FEV1 / FVC (%) 83.3 ± 1.5 78.9 ± 2.7 65.7 ± 1.8 **††
FEV1 (%predicted) 111.1 ± 2.6 101.3 ± 4.1 * 83.5 ± 1.6 **††
PaO2 (mmHg) 83.0 ± 1.6 76.2 ± 2.9 73.6 ± 4.6
PaCO2 (mmHg) 39.1 ± 1.4 41.0 ± 1.1 39.3 ± 1.3
Type of lung cancers
(number of subjects)
adenocarcinoma (5), AAH (1),
metastasis of colon cancer (1),
adenocarcinoma (4), SCC (3) adenocarcinoma (1), SCC (2), metastasis
of colon cancer (1), LCC (1), LCNEC (1)
Results are means ± SEMs. Comparisons between groups were made by Student's t-tests (* p≤ 0.05, ** p≤ 0.01, compared with non-smokers; †† p≤ 0.01,
compared with smokers without COPD.). AAH; atypical adenomatous hyperplasia, SCC; squamous cell carcinoma, LCC; large cell carcinoma, LCNEC; large cell
neuroendocrine carcinoma.
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Seiki, Tokyo, Japan) and stained with May-Grünwald-
Giemsa stain for differential cell counts; differentials
were done in a blinded manner. Cellular total RNA was
isolated using ISOGEN (Wako Pure Chemicals, Osaka,
Japan), quantified by spectrophotometry, and reverse
transcribed using a TaqMan Gold RT-PCR Kit (Applied
Biosystems, Foster City, CA). cDNA samples were ana-
lyzed by real-time quantitative PCR using a Perkin-
Elmer Applied Biosystems prism model 7700 sequence
detection system, as previously described [12].
Specimens for Histochemical Analysis
Lung tissue specimens were obtained from lobectomies
for lung cancer treatment. These were obtained from 6
male patients with mild to moderate COPD (FEV1/FVC:
57.3-69.5%; %predicted FEV1: 78.6-87.9% after inhaling a
beta-2 bronchodilator), 7 smokers (FEV1/FVC: 70.2-
85.1%), and 7 non-smokers (FEV1/FVC: 78.6-89.4%). All
smokers and non-smokers did not show COPD or
emphysematous changes based on high-resolution com-
puted tomography (Table 3). All smoking-related COPD
patients and without α1-antitrypsin deficiency exhibited
irreversible airflow obstruction. They had mild symptoms,
such as cough, sputum, and exertional breathlessness,
without need for therapy. All subjects had no symptoms
or history of asthma or allergic diseases.
For immunohistochemical analyses, an anti-CLCA1
antibody was produced in rabbits as previously described
[12]. Anti-MUC5AC antibody was from LabVision Cor-
poration (Fremont, CA) and anti-IL-13Rα antibody was
from Techne Corporation (Minneapolis, MN). Frozen
tissue sections were fixed with 4% paraformaldehyde and
incubated with antibodies. The secondary antibody used
was ENVISION+ peroxidase (Dako, Glostrup, Denmark).Color was developed after incubation with DAB+ (Dako).
Periodic acid Schiff (PAS) staining was used for mucus
detection. Stained sections were counterstained with
hematoxylin. For each patient specimen, airway epithe-
lial areas were determined in a blinded manner for 6
randomly selected sites of well-preserved airway epithe-
lium. Computer-assisted quantification of the staining in
the selected areas was performed using MacSCOPE
(Mitani Corporation, Fukui, Japan).
Statistical Analysis
Results are expressed as means ± SEMs. Comparisons be-
tween groups were performed using Student's t-test for
paired or unpaired data with Holm’s corrections. Asso-
ciations between variables were assessed by Pearson cor-
relation coefficients. P-values ≤ 0.05 were considered
significant. Statistical analyses used SAS System Version
8.2 (SAS Institute Inc., Cary, NC).
Results
Quantitative analysis of CLCA1 mRNA in
induced-sputum cells
CLCA1 mRNA expression levels were determined in the
induced-sputum cells of 20 COPD patients, 5 smokers
without COPD, and 13 healthy non-smokers. Table 2
shows the differential characteristics of the inflammatory
cells observed in these sputum samples. Compared with
samples from non-smokers, there were increased propor-
tions of neutrophils (82.5 ± 4.0%, p = 0.009) and eosino-
phils (5.5 ± 2.0%, p = 0.05) in COPD patient samples,
which was consistent with COPD. Smokers also showed a
tendency for an increased proportion of neutrophils
(73.8 ± 11.8%). In addition, COPD patient samples had
a significantly decreased proportion of macrophages
(8.3 ± 2.8%, p = 0.0004). This indicated that the origin of
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central airways, as macrophages are generally located in
alveolar areas or the peripheral airways. Using real-time
quantitative PCR analyses, there was a significant increase
in the expression of CLCA1 mRNA per 10,000 copies of
GAPDH mRNA in sputum cells from COPD patients
(579 ± 179 copies, p = 0.02) compared to cells from non-
smokers (73± 26 copies) (Figure 1). No significant differ-
ence was found between smokers (148± 81 copies) and
non-smokers, even though there was a tendency for
increased CLCA1 mRNA expression in smokers. In
addition, there was a significant positive correlation be-
tween CLCA1 mRNA expression and the proportions of
neutrophils (r = 0.34, p = 0.04). There were no significant
correlations with other inflammatory cells (results not
shown). Because neutrophil infiltration is a major patho-
logical feature of COPD, the observed positive correl-
ation suggested that CLCA1 expression was induced
during the course of COPD development.
CLCA1 protein expression in airway epithelia
Using immunohistochemical staining with an anti-CLCA1
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Figure 1 Real-time quantitative PCR analyses of CLCA1 mRNA
expression in induced sputum cells. Induced sputum samples
were obtained from non-smokers (circles, n = 13), smokers without
COPD (triangles, n = 5), and COPD patients (squares, n = 20), as
described in Methods. Group mean values are shown by horizontal
lines. CLCA1 mRNA expression (normalized to that of GAPDH mRNA)
was significantly greater for COPD patients’ cells than for non-smokers’
cells. * p≤ 0.05, Student’s t-test.tissue sections from non-smokers, smokers without
COPD, and COPD patients (Figure 2). For smokers
(Figure 2B, 2E) and COPD patients (Figure 2C, 2F), there
was prominent CLCA1 protein expression in the airway
epithelia (bronchioles and terminal bronchioles) and
minimal expression in smooth muscles. In contrast, few
CLCA1-expressing cells were detected in the lung sec-
tions from non-smokers (Figure 2A, 2D). To evaluate
relationships between CLCA1 protein expression and
COPD clinical characteristics, we performed semi-
quantitative image analyses of stained sections from 6
COPD patients, 7 smokers without COPD, and 7 non-
smokers. For each sample, the total areas of airway epi-
thelia were measured for a minimum of 6 different sites
of well-preserved airway epithelium; these results were
expressed as units per millimeter of basal lamina. The
average lengths of basal lamina per unit area were
2.4 ± 0.1 mm in non-smokers, 2.5 ± 0.4 mm in smokers,
and 2.5 ± 0.1 mm in COPD patients, which established
that these comparisons were made among airway epithe-
lia of similar sizes. The average area of CLCA1-expressing
epithelium per millimeter of basal lamina was signifi-
cantly greater for smokers (5232± 1126 μm2, p = 0.02)
and COPD patients (6954 ± 1504 μm2, p = 0.002) than
for non-smokers (1524 ± 326 μm2) (Figure 3). No signifi-
cant difference was found between smokers and COPD
patients.
Relationships between CLCA1 protein expression and
lung function parameters
We also assessed the relationships between CLCA1 pro-
tein expression image data and different clinical para-
meters shown in Table 3 (Figure 4). There were significant
negative correlations between CLCA1 protein expression
with FEV1/FVC (r=−0.57, p = 0.01, Figure 4E) and %pre-
dicted FEV1 (r =−0.56, p = 0.01, Figure 4F). In contrast,
other clinical variables, including age, Brinkman index
(BI), VC, FEV1, PaO2, and PaCO2, did not show significant
correlations with CLCA1 protein expression in airway
epithelia.
Histochemical comparison of CLCA1 protein expression
and mucus production
To evaluate the relationship between CLCA1 protein ex-
pression and mucus production in the airway epithelium,
we used PAS staining and CLCA1 immunostaining for
serial lung sections (Figure 5) and quantified the image
data for these stained sections. The average area of PAS-
stained epithelium per millimeter of basal lamina was sig-
nificantly larger for COPD patients (6042 ± 1241 μm2,
p = 0.003) and smokers without COPD (4471± 706 μm2,
p = 0.04) than for non-smokers (1823 ± 615 μm2)
(Figure 6A). No significant difference was found between









Figure 2 CLCA1 protein expression in airway epithelium. Immunohistochemical staining for CLCA1 in lung sections from (A) a non-smoker,
(B) a smoker without COPD, and (C) a COPD patient. (A-C) Scale bars = 100 μm. CLCA1 protein was strongly expressed in the airway epithelia
(bronchioles and terminal bronchioles) and minimally expressed in smooth muscles of the smoker and COPD patient. (D-F) Magnified images of
panel A (D), panel B (E), and panel C (F). (G-I) Control experiments using rabbit IgG for the same lung sections from (G) a non-smoker, (H) a
smoker without COPD, and (I) a COPD patient (D-I: scale bars = 40 μm).
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patients. We also compared PAS-stained epithelium and
CLCA1-expressing epithelium (Figure 6B). The area of
PAS-stained epithelium was significantly positively corre-
lated with the area of CLCA1-expressing epithelium
(r = 0.67, p = 0.001). These results suggested that CLCA1
may play a critical role in mucus production in the air-
way epithelia of smokers and COPD patients, similar to
what is observed in asthma.
Relationship between CLCA1 expression and an IL-13
signal in COPD
In a previous report, the expression of CLCA1 and
MUC5AC, one of the mucin proteins, was induced by
stimulating human bronchial epithelial cells with IL-13
[14]. To examine a possible relationship between CLCA1
expression and an IL-13 signal in COPD, we immunos-
tained lung sections from a COPD patient for MUC5AC
and IL-13 receptor-alpha (IL-13Rα). MUC5AC protein
was detected in airway epithelia, and MUC5AC expres-
sion mostly coincided with the expression of CLCA1
(Figure 7A, 7B), as previously reported in asthma [12].
In contrast, there was little expression of IL-13Rα pro-
tein in the airway epithelia of this COPD patient
(Figure 7C), whereas IL-13Rα expression was observed
in the airway epithelia of asthmatic patients [15]. Theseresults suggest that CLCA1 expression in COPD may
be induced via a pathway that is different from that in
asthma.
Discussion
We previously established that the expression of CLCA1
was associated with asthma pathology [11,12]. In this re-
port, we investigated the possibility that CLCA1 expres-
sion was associated with COPD pathology, characterized
by irreversible airflow obstruction and chronic mucus
hypersecretion. CLCA1 mRNA expression in induced
sputum cells tended to increase with smoking history,
and there was a significant increase in these cells from
COPD patients. Immunohistochemical analyses using
frozen lung tissue sections from non-smokers, smokers
without COPD, and COPD patients showed that CLCA1
protein expression was increased in the lung tissues of
smokers and COPD patients. These results suggest that
CLCA1 protein expression is gradually up-regulated due
to smoking.
Wang et al. reported that the expression of CLCA1
mRNA, but not protein, was increased in the airways of
Chinese patients with COPD [16]. In their study, they
examined these expressions in non-smokers and former
smokers who had given up smoking for more than






































p = 0.02 *
p = 0.002 **
Figure 3 Semi-quantitative image analyses of airway epithelium.
Total CLCA1-expressing areas of epithelia were determined with a
computerized image analysis system as described in Methods for
non-smokers (circles, n = 7), smokers without COPD (triangles, n = 7),
and COPD patients (squares, n = 6). Group mean values are shown
by horizontal lines. * p≤ 0.05, ** p≤ 0.01, Student’s t-test.
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expression of CLCA1 in the airways of patients with ob-
structive chronic bronchitis, but they did not discuss the
relationship between CLCA1 and smoking [17]. It has
been shown that cigarette smoke exposure induced the
expression of CLCA1 mRNA in the trachea and lung tis-
sues of rats [18]. Our results also suggest the importance
of cigarette smoking for CLCA1 expression in the airway
for those with a smoking history and for COPD patients.
Furthermore, we identified significant negative correla-
tions between CLCA1 expression and lung function
results, including FEV1/FVC and %predicted FEV1.
CLCA1 protein expression was gradually up-regulated
due to smoking and may be associated in some way with
impaired lung function. This is the first study to demon-
strate a critical relationship between CLCA1 expression,
smoking, and COPD.
Airway mucus obstruction is a common feature of
COPD, asthma, and many respiratory diseases [19-22].
CLCA1 is one of the key molecules associated with
mucus production and secretion by airway epithelial
cells in bronchial asthma. CLCA1 is found in bronchial
epithelium, particularly in mucus-producing goblet cells,
and its protein expression levels are highly correlatedwith the levels of MUC5AC expression and PAS staining
in asthmatics’ tissues [12]. In this study, we found good
correlations between PAS-stained areas, CLCA1-
expressing areas, and MUC5AC-expressing areas in the
airway epithelia of smokers and COPD patients. COPD
pathology is specifically associated with an increased ex-
pression of MUC5AC in the bronchiolar epithelium
[23]. Our results suggest that CLCA1 plays a critical role
in COPD by inducing mucus production in the airway
epithelia, similar to what is observed in asthma.
In this study, we identified that cigarette smoking was
implicated in the pathophysiology of COPD by inducing
mucus overproduction via CLCA1 expression. However,
the mechanism by which smoking induces CLCA1 ex-
pression remains poorly understood. In asthma, IL-13 is
a key molecule that links CLCA1 expression with mucus
production. IL-13 stimulation can induce CLCA1 and
MUC5AC expression in normal human bronchial epi-
thelial cells and murine asthma models [14,24]. How-
ever, when we examined for the expression of IL-13Rα
protein in the airway epithelia of COPD patients, which
would suggest the presence of an IL-13 signaling path-
way, we were unable to detect IL-13Rα protein expres-
sion. Although both COPD and asthma are associated
with chronic inflammation of the respiratory tract, there
are marked differences in the inflammatory cells and
mediators involved in these two diseases [19]. COPD
pathology is mainly associated with neutrophils, macro-
phages, CD8+ T cells, Th1 cytokines, and IL-8, whereas
asthma pathology is associated with eosinophils, macro-
phages, Th2 cytokines, and eotaxin. Although the par-
ticipation of IL-13 and other Th2 cytokines in COPD,
including chronic bronchitis, has also been reported in
several studies [25,26], they may be not important con-
tributors to CLCA1 expression in COPD.
Multiple stimuli, including oxidants in cigarette smoke
and cytokines produced by inflammatory cells, may in-
duce CLCA1 expression and enhance mucus hypersecre-
tion. It has been reported that chronic administration of
TNF-α, one of the cytokines induced by cigarette smoke,
increased the expression of mCLCA3 (mouse counter-
part of CLCA1) and MUC5AC mRNA in mouse lung
tissues [27]. TNF-α enhances the expression of epider-
mal growth factor receptor (EGF-R), which co-localizes
with MUC-5 AC protein [28]. Hegab et al. found that
cigarette smoke induced the expression of EGF-R
mRNA, as well as those of rCLCA1 and MUC5AC [18].
They also reported that a selective EGF-R tyrosine kin-
ase inhibitor, AG-1478, and a CLCA1 inhibitor, niflumic
acid, blocked EGF-induced MUC5AC expression and
mucus staining in the human airway epithelial cell line
NCI-H292. These studies suggest that cigarette smoke
activation of EGF-R signaling may be involved in CLCA1
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Figure 4 Correlations between lung function parameters and CLCA1-expressing epithelia. (A) Age and CLCA1 protein expression.
(B) Brinkman index and CLCA1. (C) %predicted VC and CLCA1. (D) FEV1 and CLCA1. (E) FEV1/FVC and CLCA1. (F) %predicted FEV1 and CLCA1.
(G) PaO2 and CLCA1. (H) PaCO2 and CLCA1. Results are for non-smokers (circles, n = 7), smokers without COPD (triangles, n = 7), and COPD
patients (squares, n = 6). Associations between variables were assessed by Pearson correlation coefficients (* p≤ 0.05).







Figure 5 Coincidence of PAS-stained areas and CLCA1-expressing cells in airway epithelium. Lung sections were stained with PAS (A-C) or
immunohistochemically stained with anti-CLCA1 antibody (D-F). (A, D) Airway epithelium of a non-smoker. Few mucus and CLCA1-expressing
cells were detected. (B, E) Airway epithelium of a smoker without COPD. Increased numbers of mucus secretory cells, mostly goblet cells, were
observed. (C, F) Airway epithelium of a COPD patient. Significant coincidence between mucus overproduction and CLCA1 expression was
observed. Scale bars = 50 μm.
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http://respiratory-research.com/content/13/1/55IL-17 induced by cigarette smoke may also be one of
the key molecules that connect CLCA1 expression, mucus
production, smoking, and COPD. Hashimoto et al.
reported that STAT1 KO mice infected with respiratory
syncytial virus (RSV) had upregulated mCLCA3 and
MUC5AC expressions and IL-17 production in the lungs
[29]. IL-17 is expressed by macrophages, neutrophils,
CD4+, and CD8+ T cells in the airways of COPD patients























































Figure 6 Semi-quantitative image analyses of PAS-stained epithelium
smokers without COPD (triangles, n = 7), and COPD patients (squares, n = 6
described in Methods. Group mean values are shown by horizontal lines. *
expression and PAS-stained areas in airway epithelium (Pearson’s r = 0.67, *[30,31]. Moreover, the overexpression of IL-17F in murine
lung epithelium results in lymphocyte and macrophage in-
filtration and mucus hyperplasia [32]. These studies sug-
gest that IL-17 induced by cigarette smoke may lead to
CLCA1 expression and mucus hyperplasia, which can ex-
acerbate COPD. However, in this study we could not es-
tablish these hypotheses. Additional studies will be needed
to identify the mechanism(s) responsible for mucus induc-
tion via CLCA1 expression in COPD patients.PAS-stained epithelium ( m2/mm)
r = 0.67
p = 0.001**
. (A) The epithelial areas of interest for non-smokers (circles, n = 7),
) were determined with a computerized image analysis system, as
p≤ 0.05, ** p≤ 0.01, Student’s t-test. (B) Correlation between CLCA1
* p≤ 0.01).
A B C
Figure 7 Coincidence of CLCA1 expression and MUC5AC expression, but not IL-13 receptor expression. Lung sections from a COPD
patient were immunohistochemically stained with (A) anti-CLCA1 antibody, (B) anti-MUC5AC antibody, or (C) anti-IL-13Rα antibody. Scale
bars = 200 μm.
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Taken together, CLCA1 expression was increased in ac-
cordance with smoking history and was significantly
increased in the lungs of COPD patients. CLCA1 ex-
pression was significantly correlated with neutrophil in-
filtration, respiratory disability, and mucus production in
airway epithelia. CLCA1 may contribute to the develop-
ment and pathogenesis of COPD by inducing mucus
production. Targeting CLCA1 may prove to be an effect-
ive therapeutic approach for treating COPD.
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